ML-14 LOW INVASIVE APPROACH FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATMENT INVOLVING RITUXIMAB–METHOTREXATE + PROCARBAZINE + VINCRISTINE AND TRIPLE INTRATHECAL INJECTION

摘要

Although the treatment outcomes of primary central nervous system lymphoma (PCNSL) with multiple treatment regimens involving high–dose methotrexate (MTX)–based multiagent chemotherapy have improved compared with the outcomes with high–dose methotrexate therapy in recent years, its regimen has not been established. Additionally, it is controversial whether intrathecal (IT) MTX injection can be included in a regimen. Our facilities treat PCNSL with R–MPV (rituximab–methotrexate + procarbazine + vincristine) and triple IT injection (methotrexate + Ara C + prednisolone). Here we report a low invasive approach for PCNSL treatment involving R–MPV therapy and triple IT injection.